Saturday 17 October 2026
Export ADXN’s income statement to Excel — free account
Addex Therapeutics Ltd. Sponsored ADR
ADXN Healthcare Biotechnology
In the quarter to June 2026, revenue fell 100.8%, EPS grew 25.7% and free cash flow fell 2.73%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
2.76
0.26
−8.61%
Follow ADXN
Addex Therapeutics Ltd. Sponsored ADR (ADXN) P/E ratio
Addex Therapeutics Ltd. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.8× (October 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.8× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Dec 2024 | 0.8× | (51.32%) |
| Sep 2024 | 1.6× | 74.86% |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 1.8×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CLDI Calidi Biotherapeutics, Inc. compare | n/m |
| ADXN Addex Therapeutics Ltd. Sponsored ADR | n/m |
| REVB Revelation Biosciences, Inc. compare | n/m |
| PBLA Panbela Therapeutics Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| EOCN Eocene Ltd. compare | n/m |
| CMND Clearmind Medicine Inc. compare | n/m |
| APVO Aptevo Therapeutics Inc. compare | 0.0× |
| GRI GRI Bio, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)